English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 01/11/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 59.34%
Price change 2019 → 2020: 57.54%
Price change 2020 → 2021: 29.61%
Price change 2021 → 2022: -44.35%
Price change 2022 → 2023: -23.21%
Price change 2023 → 2024: 1.74%
Price change 2024 → 2025: -7.77%
Price change 2025 → 2026: 22.84%
Price change 2026 (year to date): 21.92%
Financial growth
Revenue CAGR (8 years): 1.74%
Earnings CAGR (8 years): 11.22%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.21
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 40.11
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 4.65% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="BIO" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. | 40.1 | 0.20 | +2.0 % | 🔒 |
| bioMérieux S.A. | 22.8 | 0.11 | +7.6 % | – |
| Oscar Health, Inc. | 21.7 | 0.44 | +66.3 % | – |
| Viatris Inc. | 7.5 | 1.00 | +6.6 % | – |
| BioNTech SE | – | 0.01 | +60.8 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Bio-Rad Laboratories, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 2.5 bn | 3.8 bn | 149.8 % | n/a |
| 2021 | 2.9 bn | 4.3 bn | 145.6 % | +14.8 % |
| 2022 | 2.8 bn | -3.6 bn | -129.4 % | -4.1 % |
| 2023 | 2.7 bn | -637 m | -23.9 % | -4.7 % |
| 2024 | 2.6 bn | -1.8 bn | -71.9 % | -3.9 % |
| 2025 | 2.6 bn | 760 m | 29.4 % | +0.7 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Bio-Rad Laboratories, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 870 m | 1.8 bn | 1.6 bn | 1.7 bn | 1.5 bn |
| Total Debt | 223 m | 1.4 bn | 1.4 bn | 1.4 bn | 1.5 bn |
| Net Debt | -247 m | 954 m | 1.0 bn | 887 m | 999 m |
| Equity | 13.7 bn | 9.6 bn | 8.7 bn | 6.6 bn | 7.5 bn |
| Total assets | 17.8 bn | 13.5 bn | 12.3 bn | 9.4 bn | 10.6 bn |
| Operating cash flow | 669 m | 194 m | 375 m | 455 m | 532 m |
| Investments (capex) | 134 m | 113 m | 157 m | 166 m | 158 m |
| Free cash-flow | 536 m | 80.3 m | 218 m | 266 m | 375 m |
| Share buybacks | 50.0 m | 216 m | 429 m | 204 m | 296 m |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Bio-Rad Laboratories, Inc. compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Bio-Rad Laboratories, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Bio-Rad Laboratories, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 04/08/2026 | 2.62 | 1.75 | +49.7 % |
| 30/04/2026 | 1.89 | 1.97 | -4.1 % |
| 12/02/2026 | 2.51 | 2.57 | -2.3 % |
| 29/10/2025 | 2.26 | 2.30 | -1.7 % |
| 31/07/2025 | 2.61 | 1.93 | +35.2 % |
| 01/05/2025 | 2.54 | 1.73 | +46.8 % |
Stock splits
| Date | Operation |
|---|---|
| 08/03/2002 | split: 2 shares for 1 |
| 03/06/1996 | split: 3 shares for 2 |
| 11/06/1986 | split: 3 shares for 2 |
| 01/08/1985 | split: 3 shares for 2 |
| 18/03/1980 | split: 2 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Bio-Rad Laboratories, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| Vanguard Group | 1.8 m | 538 m | 0.0 % | -1.1 % | 2025Q4 |
| BlackRock | 1.7 m | 499 m | 0.0 % | +1.1 % | 2026Q2 |
| State Street | 1.1 m | 336 m | 0.0 % | +104.4 % | 2026Q2 |
| Ariel Investments | 816,751 | 240 m | 2.4 % | +3.9 % | 2026Q2 |
| Bank of America | 490,412 | 144 m | 0.0 % | +10.2 % | 2026Q2 |
| Capital World Investors | 462,457 | 136 m | 0.0 % | +2.8 % | 2026Q2 |
| Capital Research Global Investors | 443,483 | 130 m | 0.0 % | +15.0 % | 2026Q2 |
| Geode Capital Management | 347,575 | 102 m | 0.0 % | -4.7 % | 2026Q2 |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Bio-Rad Laboratories, Inc.
What is the Bio-Rad Laboratories, Inc. share price?
Latest recorded price: 381.57 USD on 06/11/2026, for a market cap of 10.3 bn USD.
What is the revenue of Bio-Rad Laboratories, Inc.?
2.6 bn USD for fiscal year 2025, with net income of 760 m USD (net margin 29.4 %).
What do analysts say about Bio-Rad Laboratories, Inc.?
Out of 14 analysts: 8 buy or strong buy, 6 hold, 0 sell or strong sell.
What is the P/E ratio of Bio-Rad Laboratories, Inc.?
Trailing 12-month P/E of 41.1, against 26.8 for the sector median on the same exchange (10-year median: 22.3).
Is Bio-Rad Laboratories, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0905722072).
How many employees does Bio-Rad Laboratories, Inc. have?
7,700 full-time employees according to the latest published profile.
Who runs Bio-Rad Laboratories, Inc.?
Norman D. Schwartz is the company's chief executive.
Which large funds own Bio-Rad Laboratories, Inc.?
As of 2026Q2, among the large funds tracked: Vanguard Group, BlackRock, State Street, Ariel Investments, Bank of America.